SavedAdd your journal

Journals / Türkderm Türk deri hastalıkları ve frengi arşivi / 2022 / Cilt: 56 - Sayı: 1

Ustekinumab

Murat BORLU
Pages
48–51
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Other advantages of ustekinumab include ease of use in obese patients as its dose can be adjusted according to body weight and its administration every 12 weeks in the maintenance period.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ustekinumab is an antagonistic human monoclonal immunoglobulin G1 antibody that targets p40, a common subunit of interleukin-12 (IL-12) and IL-23.
📊
Key Findings & Data:In clinical trials, 66-81% of the patients using ustekinumab achieved a PASI75 response.
💡
Conclusion & Impact:Other advantages of ustekinumab include ease of use in obese patients as its dose can be adjusted according to body weight and its administration every 12 weeks in the maintenance period.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Ustekinumab is an antagonistic human monoclonal immunoglobulin G1 antibody that targets p40, a common subunit of interleukin-12 (IL-12) and IL-23. In clinical trials, 66-81% of the patients using ustekinumab achieved a PASI75 response. Its long drug survival time has been found remarkable in real-world experiences. Other advantages of ustekinumab include ease of use in obese patients as its dose can be adjusted according to body weight and its administration every 12 weeks in the maintenance period.

Özet

Ustekinumab interlökin-12 (IL-12) ve IL-23’ün ortak alt birimi p40’ı hedef alan immünoglobulin G1 yapısında bir monoklonal antikordur. Klinik araştırmalarda PAŞİ75 yanıtı sağlanan hasta oranları %66 ile 81 arasında değişmektedir. Gerçek yaşam çalışmalarında ise uzun ilaç sağkalım süresi ile öne çıkmaktadır. Vücut ağırlığına göre doz seçimi yapıldığı için obez hastalarda kullanım kolaylığı ve idame döneminde 12 haftada bir uygulanması ustekinumabın diğer avantajlarıdır

🔖

Cite This Article

BORLU, M. (2022). Ustekinumab. Türkderm Türk deri hastalıkları ve frengi arşivi, Cilt: 56 - Sayı: 1, 48–51. https://ajindex.com/articles/622409

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Kimball AB, Papp KA, Wasfi Y, et al.: Long term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013;27:1535-45
  2. Nast A, Boehncke WH, Mrowietz U, et al.: S3-Guidelines on the treatment of psoriasis vulgaris (English version) Update. J Dtsch Dermatol Ges 2012;10(Suppl2):1-95
  3. Croxtall JD: Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 2011;71:1731-53
  4. Luo J, Wu SJ, Lacy ER, et al.: Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol 2010;402:797-812
  5. Smith CH, Anstey AV, Barker JN, et al.: British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019
  6. Langley R, et al.: Poster presented at the EADV. Prague, Czech Republic 2012;P976
  7. Nast A, Gisondi P, Ormerod AD, et al.: European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short versionEDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015;29:2277-94
  8. Leonardi CL, Kimball AB, Papp KA, et al.: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74
  9. Papp KA, Langley RG, Lebwohl M, et al.: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 2). Lancet 2008;371:1675-84
  10. Griffiths CE, Strober BE, van de Kerkhof P, et al.: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118- 28
  11. Kimball AB, Gordon KB, Fakharzadeh S, et al.: Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012;166:861-72
  12. Clemmensen A, Spon M, Skov L, Zachariae C, Gniadecki R: Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011;25:1037-40
  13. Takahashi N, Noda S, Taniguchi T, Adachi M: Efficacy comparison of ustekinumab between anti-tumor necrosis factor- drug-naïve and anti-tumor necrosis factor- drug-resistant Japanese psoriasis cases. Int J Dermatol 2015;54:11